Par Pharmaceutical, a generic pharmaceutical company was established in 1978 in the United States. Par Pharmaceutical operates Par Pharmaceutical, a generic drug division, Strativa Pharmaceuticals, a proprietary products division and JHP Pharmaceuticals, a subsidiary of Par Pharmaceuticals. It is noted for introducing genetic versions of several major pharmaceutical products like Luvox CR, Toprol-XL, Wellbutrin XL, Tussionex, Maxalt-MLT and Lamictal XR. Par Pharmaceutical is a member of the Transmucosal Immediate Release Fentanyl (TIRF) of the Risk Evaluation and Mitigation Strategy (REMS) Program who main purpose is to minimise the risk of abuse, addiction and serious complications due to medication errors with the use of TIRF medicines. The TIRF program is an FDA-acquired program that is designed to ensure minimal or no complications to patients undergoing treatment while ensuring appropriate usage of the medicines. The REMS is a risk management program that ensures that the benefits of a drug outweigh its risks.
The following is the list of scholars from Par Pharmaceutical who contributed and/or serves as editors for one or more OMICS International journals and conferences
The following is the list of proceedings by scholars from Par Pharmaceutical that are published in OMICS International journals and conferences.